Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

PHASE4

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated \[Study would not complete enrollment target until 2026 with results available in 2027. The information will not be useful at that time.\]

Conditions

Migraine

Interventions

DRUG: Placebo
DRUG: Erenumab

Sponsor

Amgen

Collaborators

[object Object]